Endpoints News 生物医药· Max Gelman·· 2 小时前AI 评分55
默沙东的抗体药物偶联物在胃癌 III 期研究中成功
Merck gets another Phase 3 win for sac-TMT, this time in gastric cancer
AI 导读
默沙东的抗体药物偶联物在胃癌 III 期研究中成功,可能缓解 Keytruda 的专利悬崖压力。
正文
An experimental antibody-drug conjugate from Merck has succeeded in another Phase 3 cancer study, potentially helping offset Keytruda’s looming patent cliff.
Merck
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news